The primary objective of this study was to assess the effect of a standard high‐fat meal on
the single‐dose (60 mg) pharmacokinetics (PK) of edoxaban in healthy Japanese and …

This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
study of a single ascending dose (SAD) and a multiple ascending dose (MAD) of the oral …

This study determined the mass balance and pharmacokinetics of edoxaban in humans after
oral administration of [14C] edoxaban. After oral administration of 60 mg (as active moiety) of …

Background Edoxaban is an oral, once‐daily, direct factor Xa inhibitor under investigation
for stroke prevention in patients with atrial fibrillation and for treatment and secondary …

Long-term anticoagulation treatment with warfarin has been associated with a number of
limitations in clinical practice and there is a need for more convenient long-term …

Introduction This phase I, open-label, multiple-dose, two-treatment study assessed the
relationship between edoxaban equivalent concentration derived from an anti-FXa assay …

Edoxaban, a once daily non-vitamin K antagonist oral anticoagulant, is a direct, selective,
reversible inhibitor of factor Xa (FXa). In healthy subjects, single oral doses of edoxaban …

Edoxaban, a once‐daily, oral, direct factor Xa inhibitor, is approved for stroke prevention in
nonvalvular atrial fibrillation and venous thromboembolism treatment. This study examined …

Background Edoxaban is an orally active, direct factor Xa inhibitor indicated to reduce the
risk of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment of …

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in
patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) …